Sanofi inks $1B deal to sell autoimmune disorder therapy
Sanofi (SNY) sells global rights to Enjaymo treatment for cold agglutinin disease to Recordati (RCDTF) in a deal worth up to ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE
Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin ...
The American Journal of Managed Care9d
Association Between Hypertensive Disorders of Pregnancy, Cardiovascular Severe Maternal Morbidity During Delivery Hospitalization
Hemolysis, elevated liver enzymes, low platelet (HELLP) syndrome, and severe preeclampsia significantly elevate ...
Healthline29d
Understanding Warm and Cold Hemolytic Anemia
Hemolysis is your body’s natural process of removing old or dysfunctional red blood cells. Certain health conditions, medications, or recent infections can sometimes cause hemolysis to go into ...
ahajournals.org1mon
Characterization and Clinical Significance of Hemolysis After Pulsed Field Ablation for Atrial Fibrillation: Results of a Multicenter Analysis
While the susceptibility of erythrocytes to electroporation is well established, the effect of cardiac PFA technologies on hemolysis has remained underreported. The aim of this study was to ...